AN2 Therapeutics to Participate at Upcoming Investor Conferences

AN2 Therapeutics (ANTX) announced that its management will participate in three investor conferences in November 2026, including presentations by CEO Eric Easom.

Rhea-AI Impact

(Moderate)

Rhea-AI Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Tags

conferences

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

10/20/2026 - 04:13 PM EDT

MENLO PARK, Calif.--(BUSINESS WIRE)-- AN2 Therapeutics, Inc. (NASDAQ: ANTX), a clinical stage biopharmaceutical company discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today announced company management will participate in three upcoming investor conferences in November.

Details of the events are as follows:

Guggenheim 3rd Annual Healthcare Innovation Conference, November 9-11, 2026

Eric Easom, Co-Founder, Chairman, President and CEO, will participate in a fireside chat on Monday, November 9, 2026 at 9:30am ET, and members of management will be available for 1X1 meetings.

Stifel 2026 Healthcare Conference, November 10-12, 2026

Eric Easom, Co-Founder, Chairman, President and CEO, will provide a corporate overview on Tuesday, November 10, 2026 at 8:40am ET, and members of management will be available for 1X1 meetings.

Jefferies London Conference, November 16-19, 2026

Members of management will be available for 1X1 meetings on Tuesday, November 17, 2026.

Webcasts of the presentation and fireside chat can be accessed on the Investors section of the AN2 Therapeutics website at www.an2therapeutics.com. An archived replay will be available for at least 30 days following the presentation.

About AN2 Therapeutics, Inc.

AN2 Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics derived from our boron chemistry platform. Our development pipeline spans hematologic diseases, infectious diseases, and oncology with three Phase 2 studies expected to be active in 2026, two preclinical candidates, as well as advanced research programs focused on targets in oncology, bone disorders, and infectious diseases. We are committed to delivering high-impact drugs to patients that address critical unmet needs and improve health outcomes.